Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

512 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antibody-Peptide Epitope Conjugates for Personalized Cancer Therapy.
Zhang S, Yan C, Millar DG, Yang Q, Heather JM, Langenbucher A, Morton LT, Sepulveda S, Alpert E, Whelton LR, Zarrella DT, Guo M, Minogue E, Lawrence MS, Rueda BR, Spriggs DR, Lu W, Langenau DM, Cobbold M. Zhang S, et al. Among authors: langenbucher a. Cancer Res. 2022 Mar 1;82(5):773-784. doi: 10.1158/0008-5472.CAN-21-2200. Cancer Res. 2022. PMID: 34965933
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors.
Dardaei L, Wang HQ, Singh M, Fordjour P, Shaw KX, Yoda S, Kerr G, Yu K, Liang J, Cao Y, Chen Y, Lawrence MS, Langenbucher A, Gainor JF, Friboulet L, Dagogo-Jack I, Myers DT, Labrot E, Ruddy D, Parks M, Lee D, DiCecca RH, Moody S, Hao H, Mohseni M, LaMarche M, Williams J, Hoffmaster K, Caponigro G, Shaw AT, Hata AN, Benes CH, Li F, Engelman JA. Dardaei L, et al. Among authors: langenbucher a. Nat Med. 2018 May;24(4):512-517. doi: 10.1038/nm.4497. Epub 2018 Mar 5. Nat Med. 2018. PMID: 29505033 Free PMC article.
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.
Yoda S, Lin JJ, Lawrence MS, Burke BJ, Friboulet L, Langenbucher A, Dardaei L, Prutisto-Chang K, Dagogo-Jack I, Timofeevski S, Hubbeling H, Gainor JF, Ferris LA, Riley AK, Kattermann KE, Timonina D, Heist RS, Iafrate AJ, Benes CH, Lennerz JK, Mino-Kenudson M, Engelman JA, Johnson TW, Hata AN, Shaw AT. Yoda S, et al. Among authors: langenbucher a. Cancer Discov. 2018 Jun;8(6):714-729. doi: 10.1158/2159-8290.CD-17-1256. Epub 2018 Apr 12. Cancer Discov. 2018. PMID: 29650534 Free PMC article.
Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer.
Ligorio M, Sil S, Malagon-Lopez J, Nieman LT, Misale S, Di Pilato M, Ebright RY, Karabacak MN, Kulkarni AS, Liu A, Vincent Jordan N, Franses JW, Philipp J, Kreuzer J, Desai N, Arora KS, Rajurkar M, Horwitz E, Neyaz A, Tai E, Magnus NKC, Vo KD, Yashaswini CN, Marangoni F, Boukhali M, Fatherree JP, Damon LJ, Xega K, Desai R, Choz M, Bersani F, Langenbucher A, Thapar V, Morris R, Wellner UF, Schilling O, Lawrence MS, Liss AS, Rivera MN, Deshpande V, Benes CH, Maheswaran S, Haber DA, Fernandez-Del-Castillo C, Ferrone CR, Haas W, Aryee MJ, Ting DT. Ligorio M, et al. Among authors: langenbucher a. Cell. 2019 Jun 27;178(1):160-175.e27. doi: 10.1016/j.cell.2019.05.012. Epub 2019 May 30. Cell. 2019. PMID: 31155233 Free PMC article.
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer.
Dagogo-Jack I, Yoda S, Lennerz JK, Langenbucher A, Lin JJ, Rooney MM, Prutisto-Chang K, Oh A, Adams NA, Yeap BY, Chin E, Do A, Marble HD, Stevens SE, Digumarthy SR, Saxena A, Nagy RJ, Benes CH, Azzoli CG, Lawrence MS, Gainor JF, Shaw AT, Hata AN. Dagogo-Jack I, et al. Among authors: langenbucher a. Clin Cancer Res. 2020 Jun 1;26(11):2535-2545. doi: 10.1158/1078-0432.CCR-19-3906. Epub 2020 Feb 21. Clin Cancer Res. 2020. PMID: 32086345 Free PMC article.
Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition.
Lin JJ, Langenbucher A, Gupta P, Yoda S, Fetter IJ, Rooney M, Do A, Kem M, Chang KP, Oh AY, Chin E, Juric D, Corcoran RB, Dagogo-Jack I, Gainor JF, Stone JR, Lennerz JK, Lawrence MS, Hata AN, Mino-Kenudson M, Shaw AT. Lin JJ, et al. Among authors: langenbucher a. NPJ Precis Oncol. 2020 Aug 3;4:21. doi: 10.1038/s41698-020-0127-9. eCollection 2020. NPJ Precis Oncol. 2020. PMID: 32802958 Free PMC article.
HPV+ oropharyngeal squamous cell carcinomas from patients with two tumors display synchrony of viral genomes yet discordant mutational profiles and signatures.
Faden DL, Langenbucher A, Kuhs K, Lewis JS, Mirabello L, Yeager M, Boland JF, Bass S, Steinberg M, Cullen M, Lawrence MS, Ferris RL. Faden DL, et al. Among authors: langenbucher a. Carcinogenesis. 2021 Feb 11;42(1):14-20. doi: 10.1093/carcin/bgaa111. Carcinogenesis. 2021. PMID: 33075810 Free PMC article.
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer.
Lin JJ, Choudhury NJ, Yoda S, Zhu VW, Johnson TW, Sakhtemani R, Dagogo-Jack I, Digumarthy SR, Lee C, Do A, Peterson J, Prutisto-Chang K, Malik W, Hubbeling HG, Langenbucher A, Schoenfeld AJ, Falcon CJ, Temel JS, Sequist LV, Yeap BY, Lennerz JK, Shaw AT, Lawrence MS, Ou SI, Hata AN, Drilon A, Gainor JF. Lin JJ, et al. Among authors: langenbucher a. Clin Cancer Res. 2021 May 15;27(10):2899-2909. doi: 10.1158/1078-0432.CCR-21-0032. Epub 2021 Mar 8. Clin Cancer Res. 2021. PMID: 33685866 Free PMC article.
512 results